After a simple opening from Roger Green, this conversation about FGF drugs in Development includes 4 key elements:
1:05 – Roger Green discusses recent history of FGF agents and podcast episodes discussing them
2:11 – Stephen Harrison discusses the efruxifermin BALANCED Phase 2a trial in F2/F3 NASH and Cohort C with cirrhosis patients
6:59 – Arun Sanyal and Stephen Harrison discuss future prospects for FGF-21 agents
10:34 – Arun Sanyal discusses specific receptor targets for different FGF agents and why they matter
This episode has specific discussions of efruxifermin and mentions of pegbelfermin and MK-3655, the former NGM-313.